LML 134

Drug Profile

LML 134

Alternative Names: LML134

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Circadian rhythm sleep disorders
  • No development reported Sleep disorders

Most Recent Events

  • 28 Mar 2018 No recent reports of development identified for phase-I development in Sleep-disorders(In volunteers) in Germany (PO)
  • 28 Jul 2017 Phase-II clinical trials in Circadian rhythm sleep disorders in USA (unspecified route) (NCT03141086)
  • 10 May 2017 Novartis plans a phase II trial for Circadian rhythm sleep disorders (NCT03141086)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top